Your flexible one stop CDMO partner, specializing in complex biologics projects, integrating analytics, development, and GMP production services
Your flexible one stop CDMO partner, specializing in complex biologics projects, integrating analytics, development, and GMP production services
Your flexible one stop CDMO partner, specializing in complex biologics projects, integrating analytics, development, and GMP production services
ABOUT BIODEXTRIS
Built on GSK’s legacy and powered by a state-of-the-art GMP facility, Biodextris is a global biologics CDMO committed to supporting innovators from early development to commercial manufacturing."
We provide end-to-end services — including analytical development, process development, QC testing and GMP biomanufacturing — with the agility and expertise needed to bring life-changing therapies to patients worldwide.
Built on GSK’s legacy and powered by a state-of-the-art GMP facility, Biodextris is a global biologics CDMO committed to supporting innovators from early development to commercial manufacturing."
We provide end-to-end services — including analytical development, process development, QC testing and GMP biomanufacturing — with the agility and expertise needed to bring life-changing therapies to patients worldwide.
Built on GSK’s legacy and powered by a state-of-the-art GMP facility, Biodextris is a global biologics CDMO committed to supporting innovators from early development to commercial manufacturing."
We provide end-to-end services — including analytical development, process development, QC testing and GMP biomanufacturing — with the agility and expertise needed to bring life-changing therapies to patients worldwide.
OUR SERVICES
OUR SERVICES
OUR SERVICES
PROCESS
DEVELOPMENT
Development of upstream production, downstream
purification and bulk production capability for microbial, mammalian and insect cells
☑ BSL2 facilities
☑ 5-200L bioreactors
GMP BIOMANUFACTURING
High-quality protein production specialization, with a high-focus on regulatory compliance,
scalability and product
excellence.
☑ From development to GMP Phase III, with the ability to scale as your program advances
☑ 5-200L bioreactors
☑ 6,500 sq. ft. (600m²) of GMP compliant BSL2 cleanrooms
☑ Small scale aseptic Fill & Finish for vials and PFS
ANALYTICAL
DEVELOPMENT &
QUALITY CONTROL
Development of complete analytical packages and GMP compliant bio analytical
testing enabling Quality Control.
☑ Fully equipped bioanalytical lab
☑ In-house IUCH Stability Storage and Testing
☑ Robust Quality Management System
PROCESS
DEVELOPMENT
Development of upstream production, downstream
purification and bulk production capability for microbial, mammalian and insect cells
☑ BSL2 facilities
☑ 5-200L bioreactors
GMP BIOMANUFACTURING
High-quality protein production specialization, with a high-focus on regulatory compliance,
scalability and product
excellence.
☑ From development to GMP Phase III, with the ability to scale as your program advances
☑ 5-200L bioreactors
☑ 6,500 sq. ft. (600m²) of GMP compliant BSL2 cleanrooms
☑ Small scale aseptic Fill & Finish for vials and PFS
ANALYTICAL
DEVELOPMENT &
QUALITY CONTROL
Development of complete analytical packages and GMP compliant bio analytical
testing enabling Quality Control.
☑ Fully equipped bioanalytical lab
☑ In-house IUCH Stability Storage and Testing
☑ Robust Quality Management System
PROCESS
DEVELOPMENT
Development of upstream production, downstream
purification and bulk production capability for microbial, mammalian and insect cells
☑ BSL2 facilities
☑ 5-200L bioreactors
GMP BIOMANUFACTURING
High-quality protein production specialization, with a high-focus on regulatory compliance,
scalability and product
excellence.
☑ From development to GMP Phase III, with the ability to scale as your program advances
☑ 5-200L bioreactors
☑ 6,500 sq. ft. (600m²) of GMP compliant BSL2 cleanrooms
☑ Small scale aseptic Fill & Finish for vials and PFS
ANALYTICAL
DEVELOPMENT &
QUALITY CONTROL
Development of complete analytical packages and GMP compliant bio analytical
testing enabling Quality Control.
☑ Fully equipped bioanalytical lab
☑ In-house IUCH Stability Storage and Testing
☑ Robust Quality Management System
OUR FACILITY
OUR FACILITY
Our 32,000 sq. ft. (3,000 m²) state-of-the-art facility is designed
to drive innovation, collaboration, and growth at every stage of
development.
Our 32,000 sq. ft. (3,000 m²) state-of-the-art facility is designed to drive innovation, collaboration, and growth at every stage of development.
Our 32,000 sq. ft. (3,000 m²) state-of-the-art facility is designed to drive innovation, collaboration, and growth at every stage of
development.
32,000 sq. ft
32,000 sq. ft
of custom-designed
CDMO facility
of custom-designed
CDMO facility
6,500 sq. ft
6,500 sq. ft
of GMP biomanufacturing
cleanrooms
of GMP biomanufacturing
cleanrooms
8,000 sq. ft
8,000 sq. ft
of process development,
analytical & QC labs
of process development,
analytical & QC labs
2,500 sq. ft
2,500 sq. ft
2,500 sq. ft
of controlled material
warehousing
of controlled material
warehousing
Description
TESTIMONIALS
What Our Clients Say About Us
TESTIMONIALS
What Our Clients Say About Us
TESTIMONIALS
What Our Clients Say About Us
“Our vaccine product requires a new recombinant protein processing step that has never before been used in clinical manufacturing of biological products. As such, we have hard technical difficulties in manufacturing product development. However, partnership with Biodextris has produced a drug substance significantly more effective than all the materials tested to date — 17x higher neutralizing antibody response than the current market leading recombinant RSV vaccine!”
— Chris Marshall, CEO of Calder Biosciences
“Every client that we have referred to Biodextris has had nothing but positive feed-back, which has not always been the case when we’ve referred other CDMO partners”
— Business Development Officer, National Research
Council Canada
“We are very happy with the purity Biodextris was able to achieve compared to all the CDMOs we’ve worked with! Virtually 100% of the VLPs are mature: we are thrilled by the results their expertise delivered - science prevails!”
— Associate Director Analytical Development, Top 20
Global Pharma
“Our vaccine product requires a new recombinant protein processing step that has never before been used in clinical manufacturing of biological products. As such, we have hard technical difficulties in manufacturing product development. However, partnership with Biodextris has produced a drug substance significantly more effective than all the materials tested to date — 17x higher neutralizing antibody response than the current market leading recombinant RSV vaccine!”
— Chris Marshall, CEO of Calder Biosciences
“Every client that we have referred to Biodextris has had nothing but positive feed-back, which has not always been the case when we’ve referred other CDMO partners”
— Business Development Officer, National Research
Council Canada
“We are very happy with the purity Biodextris was able to achieve compared to all the CDMOs we’ve worked with! Virtually 100% of the VLPs are mature: we are thrilled by the results their expertise delivered - science prevails!”
— Associate Director Analytical Development, Top 20
Global Pharma
“Our vaccine product requires a new recombinant protein processing step that has never before been used in clinical manufacturing of biological products. As such, we have hard technical difficulties in manufacturing product development. However, partnership with Biodextris has produced a drug substance significantly more effective than all the materials tested to date — 17x higher neutralizing antibody response than the current market leading recombinant RSV vaccine!”
— Chris Marshall, CEO of Calder Biosciences
“Every client that we have referred to Biodextris has had nothing but positive feed-back, which has not always been the case when we’ve referred other CDMO partners”
— Business Development Officer, National Research
Council Canada
“We are very happy with the purity Biodextris was able to achieve compared to all the CDMOs we’ve worked with! Virtually 100% of the VLPs are mature: we are thrilled by the results their expertise delivered - science prevails!”
— Associate Director Analytical Development, Top 20
Global Pharma
GET IN TOUCH WITH OUR FRIENDLY TEAM
We welcome you to contact us with any inquiry — we will answer you shortly!